These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 21175738)

  • 1. Intracisternal enzyme replacement therapy in lysosomal storage diseases: routes of absorption into brain.
    Jolly RD; Marshall NR; Perrott MR; Dittmer KE; Hemsley KM; Beard H
    Neuropathol Appl Neurobiol; 2011 Jun; 37(4):414-22. PubMed ID: 21175738
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of cisternal sulfamidase delivery in MPS IIIA Huntaway dogs--a proof of principle study.
    Hemsley KM; Norman EJ; Crawley AC; Auclair D; King B; Fuller M; Lang DL; Dean CJ; Jolly RD; Hopwood JJ
    Mol Genet Metab; 2009 Dec; 98(4):383-92. PubMed ID: 19699666
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intracisternal enzyme replacement therapy in lysosomal storage diseases: dispersal pathways, regional enzyme concentrations and the effect of posttreatment posture.
    Jolly RD; Marshall NR; Marshall J; Hartman A; Hemsley KM; Winner LK
    Neuropathol Appl Neurobiol; 2013 Oct; 39(6):681-92. PubMed ID: 23252616
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Injection of recombinant human sulfamidase into the CSF via the cerebellomedullary cistern in MPS IIIA mice.
    Hemsley KM; King B; Hopwood JJ
    Mol Genet Metab; 2007 Mar; 90(3):313-28. PubMed ID: 17166757
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Determination of the role of injection site on the efficacy of intra-CSF enzyme replacement therapy in MPS IIIA mice.
    Beard H; Luck AJ; Hassiotis S; King B; Trim PJ; Snel MF; Hopwood JJ; Hemsley KM
    Mol Genet Metab; 2015 May; 115(1):33-40. PubMed ID: 25795516
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low-dose, continuous enzyme replacement therapy ameliorates brain pathology in the neurodegenerative lysosomal disorder mucopolysaccharidosis type IIIA.
    King B; Hassiotis S; Rozaklis T; Beard H; Trim PJ; Snel MF; Hopwood JJ; Hemsley KM
    J Neurochem; 2016 May; 137(3):409-22. PubMed ID: 26762778
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Slow, continuous enzyme replacement via spinal CSF in dogs with the paediatric-onset neurodegenerative disease, MPS IIIA.
    King B; Marshall NR; Hassiotis S; Trim PJ; Tucker J; Hattersley K; Snel MF; Jolly RD; Hopwood JJ; Hemsley KM
    J Inherit Metab Dis; 2017 May; 40(3):443-453. PubMed ID: 27832416
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel treatments and future perspectives: outcomes of intrathecal drug delivery.
    Dickson PI
    Int J Clin Pharmacol Ther; 2009; 47 Suppl 1():S124-7. PubMed ID: 20040323
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enzyme replacement reduces neuropathology in MPS IIIA dogs.
    Crawley AC; Marshall N; Beard H; Hassiotis S; Walsh V; King B; Hucker N; Fuller M; Jolly RD; Hopwood JJ; Hemsley KM
    Neurobiol Dis; 2011 Aug; 43(2):422-34. PubMed ID: 21550404
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Delivery of therapeutic protein for prevention of neurodegenerative changes: comparison of different CSF-delivery methods.
    Marshall NR; Hassiotis S; King B; Rozaklis T; Trim PJ; Duplock SK; Winner LK; Beard H; Snel MF; Jolly RD; Hopwood JJ; Hemsley KM
    Exp Neurol; 2015 Jan; 263():79-90. PubMed ID: 25246230
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of enzyme dose and dose-frequency in ameliorating substrate accumulation in MPS IIIA Huntaway dog brain.
    King B; Marshall N; Beard H; Hassiotis S; Trim PJ; Snel MF; Rozaklis T; Jolly RD; Hopwood JJ; Hemsley KM
    J Inherit Metab Dis; 2015 Mar; 38(2):341-50. PubMed ID: 25421091
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Brain Targeting in MPS-IIIA.
    Sorrentino NC; Fraldi A
    Pediatr Endocrinol Rev; 2016 Jun; 13 Suppl 1():630-8. PubMed ID: 27491210
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enzyme replacement therapy for lysosomal storage diseases.
    Lachmann RH
    Curr Opin Pediatr; 2011 Dec; 23(6):588-93. PubMed ID: 21946346
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intrathecal enzyme replacement therapy reduces lysosomal storage in the brain and meninges of the canine model of MPS I.
    Kakkis E; McEntee M; Vogler C; Le S; Levy B; Belichenko P; Mobley W; Dickson P; Hanson S; Passage M
    Mol Genet Metab; 2004; 83(1-2):163-74. PubMed ID: 15464431
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Disease stage determines the efficacy of treatment of a paediatric neurodegenerative disease.
    Hassiotis S; Beard H; Luck A; Trim PJ; King B; Snel MF; Hopwood JJ; Hemsley KM
    Eur J Neurosci; 2014 Jun; 39(12):2139-50. PubMed ID: 25068161
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enzyme-replacement therapy from birth delays the development of behavior and learning problems in mucopolysaccharidosis type IIIA mice.
    Gliddon BL; Hopwood JJ
    Pediatr Res; 2004 Jul; 56(1):65-72. PubMed ID: 15128919
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CNS penetration of intrathecal-lumbar idursulfase in the monkey, dog and mouse: implications for neurological outcomes of lysosomal storage disorder.
    Calias P; Papisov M; Pan J; Savioli N; Belov V; Huang Y; Lotterhand J; Alessandrini M; Liu N; Fischman AJ; Powell JL; Heartlein MW
    PLoS One; 2012; 7(1):e30341. PubMed ID: 22279584
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intracerebral injection of sulfamidase delays neuropathology in murine MPS-IIIA.
    Savas PS; Hemsley KM; Hopwood JJ
    Mol Genet Metab; 2004 Aug; 82(4):273-85. PubMed ID: 15308125
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of high-dose, chemically modified sulfamidase on pathology in a murine model of MPS IIIA.
    Rozaklis T; Beard H; Hassiotis S; Garcia AR; Tonini M; Luck A; Pan J; Lamsa JC; Hopwood JJ; Hemsley KM
    Exp Neurol; 2011 Jul; 230(1):123-30. PubMed ID: 21515264
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Widespread gene transduction to the central nervous system by adenovirus in utero: implication for prenatal gene therapy to brain involvement of lysosomal storage disease.
    Shen JS; Meng XL; Maeda H; Ohashi T; Eto Y
    J Gene Med; 2004 Nov; 6(11):1206-15. PubMed ID: 15459963
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.